Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Recommended Global Physics Webinars & Conferences

Europe & UK

Asia Pacific & Middle East


Heart Failure conferences 2023

About Conference

We proudly introduce the “8th World Congress on Cardiology and Heart Failure” which will be held during June 28-29, 2023 at London, UK. Heart Failure Conferences 2023 will congregate world-class cardiac surgeons, Scientists and Cardiologists to discuss methodology for ailment remediation for heart, Electrocardiography, Heart Failure, Nuclear Cardiology conferences, cardiology meetings are planned to give varying and stream adapting that will keep helpful expert next to each other of the issues impacting the expectation, finding and treatment of cardiovascular contamination. The assembling will be dealt with around the theme “The sudden heart failures and impacts created on Heart due to Co-vid 19”.

Why to go???

Heart Failure Conferences 2023 is united by a committed of network Cardiologists, Heart Surgeons, Cardiovascular experts from different parts of the world target obtaining some answers regarding Heart Diseases, this is your single most accessible opportunity to accomplish the greatest accumulation of individuals from the mending focuses, Universities, etc. This Heart Disease Conferences 2023 can coordinate seems, disperse data, meet with revenant pattern and potential scientist and find name assertion at this 2-day event an artless instructional expertise that will extend your everyday practice. The Heart Failure Conferences 2023 is meant to deliver associate fascinating forum to critically examine evidence-based methods yet as up to date best practices and clinical decision-making to succeed in our common objective of rising heart health of patients with disorder.

Attend this conference and you will:

Challenge the norm: Discuss, share your resent research and critique the latest in cardiovascular prevention and return to your practice ready to improve the care of your patients.

Lead the way: Local learning designed to empower you to transform your community through topics such as Lessons from the Leaders and Top Clinical Trials to Change Your Practice, as well as the latest in acute coronary syndrome, heart failure, valvular disease, arrhythmia and prevention.

Power your mind: realize sensible Solutions for everyday issues by victimization real-world approaches to guideline-driven care. Challenge your information in participant driven sessions as per your interest.

Ignite conversation: Network with faculty from leading cardiovascular societies round the world in an intimate setting and make connections with colleagues through shared discussion and bi-directional learning.

Strive to be your best and be a part of with us in our vision of a world wherever scientific exchange for optimum cardiovascular health and outcomes.


This conference is meant for active cardiologists, Cardiac Surgeons, Students (Young Researcher forum), Cardiology Researchers, Cardiology Faculty, From Medical University Colleges, Cardiology Associations and Societies members, Business Entrepreneurs, Training Institutes and Medical Devices Companies.


The overall goal of this conference is to look at the rising trends and evidence-based methods also as up to date best practices leading to guideline-driven, sensible cardiovascular bar and management for patients with cardiovascular diseases.





Session And Tracks

Track-1Cardiovascular Engineering

Cardiovascular Engineering stimulates innovative strategies and technological advancements within the basic understanding of the circulatory system and in cardiovascular designation and treatment applications. Original Contributions define new ideas and applications in cardiovascular mechanics, cardiology applications and diagnostic strategies, cardiac and vascular imaging, devices and instrumentation, hemodynamic observance and measurements, cardiac help, vascular grafts and artificial hearts, cardiac electrophysiology techniques, pc modeling and drug delivery systems.

Track-2: Cardio Oncology

Cardio-oncology is the intersection of heart failure conditions in patients who have been treated for cancer. New insights into however cancer therapies impact cardiovascular physiological condition and long-run effects on cancer survivors. In view of trends, similarly because the cardiovascular toxicity potential of radiation and therapy, cancer patients square measure exposed to vas morbidity and mortality over ever before. Anticancer therapies will cause important injury to the vasculature, leading to angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure (HF), independently from the direct myocardial or pericardial damage that might occur. Moreover, cancer is mostly related to a hypercoagulable state, that will increase the danger of acute thrombotic events.

Track-3: Cardiologists

cardiologist is a doctor who specializes in the studies of heart failure & its functions & also diagnosis, treatment and preventing diseases related to heart failure and blood vessels. You might also visit a cardiologist so you can learn about your risk factors for heart failure and find out what measures you can take for better heart health. Cardiology could be a field that is ever-changing speedily, New technologies as drug-eluting stents, assist devices for ventricle, and novel inflammatory markers, and imaging modalities like resonance imaging and 3D echocardiography.

Track-4: Nuclear Cardiology & Cardiac CT

Heart Failure is that the leading explanation for death within the western world. Each year inside the U.S.A, quite 500,000 men and women die from arteria coronaria ill health. During the past 20 years, major strides are created within the diagnosing and treatment of coronary failure. Nuclear cardiology has compete a pivotal role in establishing the diagnosing of cardiovascular disease and within the assessment of disease extent and also the prediction of outcomes within the setting of coronary artery disease.

Nuclear cardiology studies use noninvasive techniques to assess cardiac muscle blood flow, measure the pumping perform of the heart in addition as visualize the scale and site of a coronary failure. Among the techniques of nuclear medicine, heart muscle insertion imaging is that the foremost usually used.

Track-5: Heart and Obesity

People with a body mass index (BMI) of thirty or higher are thought of corpulent. The term avoirdupois is employed to explain the health condition of anyone considerably on top of his or her ideal healthy weight. Obesity increases the risk for heart failure and stroke. But it harms over simply the guts and vessel system. It's also a serious reason for gallstones, osteoarthritis and respiratory problems.

Obesity is intimately tangled with multiple health conditions that underlie upset as well as high pressure level, diabetes, and abnormal blood cholesterol. In addition, weight gain may be a frequent consequence of heart-damaging way selections like lack of exercise and a fat-laden diet. Obesity also can lead to heart failure. This is a significant condition within which your heart cannot pump enough blood to satisfy your body's wants.

Track-6: Heart Diagnosis & Devices

Medical diagnosis relies on info from sources like findings from a physical examination, interview with the patient or family or each, case history of the patient and family, and clinical findings as reported by laboratory tests and radiologic studies. The diagnosis of heart failure can be carried out by various methods such as by Imaging techniques, Surgeries, electrophysiology, angiography, radiography etc. Medical care is extremely essential once the heart illness is diagnosed. The aim of treatment area unit stabilizing the condition, dominant symptoms over the long run, and providing a cure once doable. Stress reduction, diet, and lifestyle changes are key in managing heart failure, but the main stays of conventional care are drugs and surgery.

Track-7: Molecular Cardiology and Hypertension

Molecular cardiology could be a new space of cardiovascular drugs that aims to use molecular biological techniques for the mechanistic investigation, diagnosis, prevention, and treatment of heart failure As an rising discipline, it's modified our abstract thinking of cardiovascular development, sickness etiology, and pathophysiology. Although molecular cardiology continues to be at a awfully early stage, it's opened a promising avenue for understanding and dominant upset. A great interest of the laboratory is that the identification of novel current factors that regulate cardiac biology, as well as aging and hypertrophy.

Hypertension is that the single most vital risk issue for stroke. It causes about 50 per cent of ischemic strokes and also increases the risk of hemorrhagic stroke. The injury that high blood pressure causes happens over time and is commonly solely diagnosed once wide injury has already happened to the body’s blood vessels. The increase in vessel risk has primarily been delineated  in terms of elevated blood pressure in those over age sixty years and elevation in blood pressure in younger people.

Track-8: Cardiac Nursing and Healthcare

Cardiac nursing is a registered nurse who specializes to work with patients who suffer from various conditions of the cardiovascular system. Cardiac nurses facilitate to treat conditions like unstable angina, heart disease, arteria sickness, symptom coronary failure, infarct and cardiac dysrhythmia beneath the direction of a heart surgeon. Cardiac nurses conjointly perform surgical  care on a surgical unit, check evaluations, cardiac observation, vascular  observation, and health assessments. Cardiac nurses add many alternative environments, together with coronary care units (CCU), cardiac catheterization, medical aid units (ICU), operational theatres, cardiac rehabilitation centers, clinical analysis, cardiac surgery wards, cardiovascular intensive care units (CVICU), and cardiac medical wards.

Track-9: Vascular Heart Disease

Vascular cardiovascular disease is characterised by injury to or a defect in one among the four heart valves: the mitral, aortic, angular  or pneumonic. In vascular cardiovascular disease, the valves become too slim and hardened (stenosis) to open absolutely or are unable to shut utterly (incompetent). Valve sickness symptoms will occur suddenly, depending upon how quickly the disease develops. Many of the symptoms are the same as those related to symptom heart disease, such as shortness of breath and wheezing after limited physical exertion and swelling of the feet, ankles, hands or abdomen (edema). The severity of vascular heart disease varies. In delicate cases there is also no symptoms, while in advanced cases, vascular heart disease may lead to congestive heart failure and other complications. Treatment depends upon the extent of the disease.

Track-10: Clinical Cardiology

Cardiology issues with diseases and disorders of the heart, like arteria coronaria sickness and symptom coronary failure. The field includes diagnosing and treatment of nonheritable heart defects, arteria coronaria sickness, heart condition, tube heart condition and electrophysiology. Although the heart and circulatory system make up your cardiovascular system. Heart works as a pump that pushes blood to the organs, tissues, and cells of your body. Blood delivers atomic number 8 and nutrients to each cell and removes the CO2 and waste product created by those cells.

Track-11: Pediatric Cardiology

Pediatric cardiology is accountable for the diagnosing of inborn heart disease defects, performing diagnostic procedures such as echocardiograms, cardiac catheterizations, and electrophysiology studies, and for the ongoing management of the sequelae of heart failure in infants, children and adolescents.

Track-12: Cardiovascular Toxicology and Pharmacology

Cardiovascular pharmacology focuses on the fundamental mechanisms of cardiovascular cells and how drugs influence the heart failure and vascular system and those parts of the nervous and endocrine systems that participate in regulating cardiovascular function. Researchers observe the results of medicine on blood pressure, blood flow in specific vascular  beds, unharness of physiological mediators, and neural activity arising from central nervous system structures.

Cardiovascular toxicology is concerned with the adverse effects of extrinsic and intrinsic stresses on the heart failure and vascular system. Extrinsic stress involves exposure to therapeutic drugs, natural products, and environmental toxicants. Intrinsic stress refers to exposure to toxic metabolites derived from nontoxic compounds such as those found in food additives and supplements. The intrinsic exposures also include secondary neurohormonal disturbance such as overproduction of inflammatory cytokines derived from pressure overload of the heart failure and counter-regulatory responses to hypertension. These deadly exposures end in alterations in organic chemistry pathways, defects in cellular structure and performance, and pathologic process of the affected circulatory system.

Track-13: Pediatric & Geriatric Cardiology

Pediatric cardiology concern all aspects of cardiopathy in infants, children, and adolescents, additionally as biology and anatomy, physiology and pharmacology, chemical science, pathology, genetics, radiology, clinical aspects, investigatory cardiology, electrophysiology and echocardiography, and cardiac surgery. Pediatric cardiology is accountable for the diagnosing of inborn coronary failure, performing arts diagnostic procedures like echocardiograms, cardiac catheterizations and electrophysiology studies. The increasing number of neonates with congenital heart failure referred to the neonatal intensive care unit reflects the increasing awareness that the defects may be present. Chest radiography and ECG rarely assist in the neonatal diagnosis.

Track-14: Cardiac Regeneration

Cardiac Regeneration could be a broad effort and comes into existence once the cardiac tissue is broken and did not regenerate the cardiac muscle. Where the most principle behind cardiac regeneration is Reparative stem cells have the potential to revive perform to broken tissue by invigorating cell growth in cardiac cells destroyed by heart illness. Reparative tools are designed to revive broken heart tissue and performance victimisation the body's natural ability to regenerate. Current therapies include such as adult stem and precursor cells, Nuclear dynamics of the heart growth, Reprogramming Fibroblasts to Cardiomyocytes, Stem cells and cell therapy.

Track-15 : Heart Disease and Heart Failure

Heart Disease could be a major reason for incapacity and premature death throughout the globe. The underlying pathology is arterial sclerosis, that develops over a few years and is sometimes advanced by the time symptoms occur, usually in time of life. Acute coronary events (heart attacks) and neural structure events (strokes) often occur suddenly and are usually fatal before medical aid are often given. Heart Conferences promotes awareness against Risk issue modification that reduces clinical events and premature death in individuals with established cardiovascular disease in addition as in those that are at high cardiovascular risk because of one or a lot of risk factors.

Heart failure, generally called symptom failure, happens once your muscle does not pump blood. Certain conditions, like narrowed arteries in your heart (coronary artery disease) or high blood pressure, gradually leave your heart too weak or stiff to fill and pump with efficiency. Not all conditions that cause cardiopathy is reversed, however treatments will improve the signs and symptoms of heart failure and assist you live longer. Lifestyle changes like exercise, reducing salt in your diet, managing stress and losing weight will improve your quality of life.

Track-16: Cardiovascular Surgeries   

Cardiac surgery are surgery on the center performed by cardiac surgeons. Every currently and once more, it's done to treat inconveniences of ischaemic coronary unhealthiness, amend inherent coronary unhealthiness, or treat controller coronary unhealthiness from totally different causes as well as carditis, rheumatic coronary illness and atherosclerosis. It also includes heart transplantation. The advancement of viscus surgery and cardiopulmonary bypass techniques has diminished the mortality rates of those surgeries to usually low positions. For instance, repairs of area unit presently assessed to possess 4–6% death rates.



Market Analysis

Visit for more related articles at Current Trends in Cardiology

According to business intelligence provider GBI Research, the global market for cardiovascular disease is expected to increase from $129.2 billion in 2015 to $146.4 billion by 2022, growing at a very modest compound annual growth rate of 1.8%. This market includes a variety of disorders like hypertension, coronary artery disorders, cardiac arrest, dyslipidemia, and thrombotic events.

The market for cardiology products and services was estimated to be worth USD 116.9 billion in 2017 and is anticipated to expand at a CAGR of 7.4% from 2017 to 2022. Among the key elements anticipated to propel development over the forecast period are the rise in the prevalence of congenital heart defects and the availability of technologically advanced cardiovascular valves, grafts, and patches.


The WHO report from May 2018 states that the rise in cardiology diseases is to blame for the region's population mortality rate in Asia and the Middle East. The global market for cardiology therapeutics is expanding quickly as new medications and medical equipment hit the market. According to our expert in cardiology market research, diabetes is one of the main causes of the current epidemic of cardiovascular disease. The primary factor fueling the expansion of the cardiology failure market is the rising incidence of chronic diseases like diabetes and heart attacks. Due to the potential for newly authorised drugs to enter the market, the size of the cardiology market is anticipated to increase in the upcoming years.

The heart failure medication Entresto from 'Novartis' was released onto the market in July 2015, and GBI Research anticipates that during the forecast period, its sales will increase significantly. Clinical trials have demonstrated the effectiveness of the combination drug Entresto. The drug is expected to generate a very high revenue of $5.7 billion by 2022 despite having a high cost of over $4 500 per patient annually.

The market's structure will change significantly as a result of the sheer volume of expirations and approvals. In accordance with the International Society for Heart and Lung Registry.

Globally, between 500 and 600 paediatric heart transplant operations are carried out each year, accounting for about 12% of all heart transplants carried out on all patients. There were also 586 paediatric heart transplants performed worldwide in 2014. A congenital heart defect or cardiomyopathy is the condition that causes heart failure in children the most frequently. Consequently, the mortality rate in children with this disorder has increased due to the rising incidence of heart failure.

The global market for heart transplants is anticipated to expand at a CAGR (Compound Annual Growth Rate) of 11.2% from 2017 to 2023. During the forecast period, it is expected that the global market for interventional cardiology will expand steadily and register a CAGR of more than 7%. The global market for interventional cardiology will experience growth in the coming years due to the rising demand for minimally invasive (MI) procedures.

The probability of Cardiovascular Diseases:


Scope and Importance

The field of medicine's cardiology is one that is constantly evolving. Young and old people alike are susceptible to heart conditions in this day and age, which are primarily brought on by their way of life and poor hygiene. The study of cardiology has become increasingly important as a result of the need to combat these diseases and their causes. With the aid of a catheter, doctors and patients can perform surgery with little risk and little blood loss thanks to interventional cardiology, a branch of cardiology that uses minimally invasive techniques to treat disorders.

The market for cardiac surgery devices is anticipated to be driven by developments in the fields of material sciences, interventional cardiology, and cryopreservation. Expanded Polytetrafluoroethylene's use in cardiovascular patches, the development of transcatheter heart valves, and the use of minimally invasive technologies like transcatheter aortic valve replacement and implantation are a few factors anticipated to boost growth during the forecasted period. In addition, one of the significant technological developments in cardiac surgery therapies that is anticipated to have a positive impact on the market is the modification of cryopreservation techniques by key players like CryoLife.


In 2021, the market for interventional cardiology devices was estimated to be worth USD 11.95 billion. From 2022 to 2030, the market is anticipated to grow at a CAGR of 3.7%. A number of factors, including intense price competition, will contribute to declining ASPs, which will restrain industry growth. These losses will be partially offset by the increase in complex lesions as well as the creation of specialised, pricy techniques to recognise and handle these complex CADs. By offering a wide variety of products in the IC device market, for instance, businesses like Abbott Laboratories continue to make money. The company has been able to maintain a significant position in this market by concentrating on launching new products.

Clinical trial delays, faulty supply chains, and a stronger focus on medical supplies and associated critical care devices are some elements that have negatively impacted the industry's expansion. Elective to semi-urgent PCI procedures, which are frequently more deferable, saw a significant decline in 2020. The severity of circumstances requiring an urgent operation has increased, and in 2020, this decline will be noticeably slower.

Similar to how IC procedure volumes, unit sales, and revenues all decreased in 2020, the market began to rebound mostly at the beginning of 2021. When a backlog of deferred procedures is cleared out in 2021 and 2022, annual growth will resume. The recovery levels of deferred procedures will be greatly impacted by the healthcare system's capacity as well as hospitals' and doctors' capacity to handle the increased patient load.

Additionally, throughout the projection period, rising patient numbers would be encouraged by government programmes to improve the affordability and accessibility of IC treatments, such as the Ayushman Bharat Yojana in India. In September 2018, the Indian government unveiled Ayushman Bharat Yojana, the largest publicly funded healthcare initiative in the world. The government aims to build a network of primary healthcare facilities centred in the community and provide insurance coverage for secondary and tertiary services to roughly half of the population of the country, with a focus on underprivileged families in rural areas. 

Product Insights

The segment with the highest revenue share in 2021—more than 35.0%—was coronary stents. In the coronary stent market category as a whole, DES typically accounts for the majority of sales. The release of next-generation DES, such as Abbott Laboratories' XIENCE series, Medtronic's Resolute Onyx, and many other well-known stents, such as the SYNERGY and Orsiro DES from Boston Scientific and BIOTRONIK, have been beneficial to the market. In comparison to their more traditional counterparts, these more modern stents offer superior deliverability, stent integrity, and lower rates of problems. Over the course of the projection period, the market for PTCA balloon catheters will also continue to grow significantly. This is partially due to the fact that there will be an increase in PCI procedures, especially in countries like India, China, and Latin America where untreated CAD is more prevalent.

The total number of IC processes has a significant impact on the market expansion for companion devices. Up until the COVID-19 pandemic's effects have subsided, accessory device sales will rise as more patients in the covered regions become eligible for Percutaneous Coronary Intervention. This will increase accessory device revenues. The accessory device market is rather large despite typically low average selling prices (ASPs) when compared to other device categories in the market because multiple devices must be used in every IC method.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Competitive benchmarking
  • Historical data & forecasts
  • Company revenue shares
  • Regional opportunities
  • Latest trends & dynamics

Regional Insights

A rising incidence of CAD and improved CAD screening, economic growth, increased government investment in healthcare, favourable reimbursement in South Korea and Australia, the expansion of the healthcare infrastructure in India and China, and the rising prevalence of a number of CAD risk factors like poor diets, smoking, and unhealthy lifestyles are all reasons why Asia Pacific held the largest revenue share of over 55.0% in 2021.

While there are numerous initiatives supporting market expansion, the government has also taken a number of measures that may serve to obstruct this development. For instance, the cost of DES was significantly decreased in January 2021 when the Chinese government implemented a centralised procurement process for high-value medical supplies. To win the national tender, the average price of DES was reduced by 93% from 2019 prices. Furthermore, imports and ASPs of domestic products would both decrease by 95% in China. This move will result in a slight decline in the Chinese IC device market over the course of the projection period because a sizable portion of IC device revenues are derived from coronary stents.

During the forecast period, it is expected that Latin America will experience exponential growth. The market will expand due to ongoing innovations, regional regulatory approval of more recent technologies like next-generation DES and BRS, and subsequent acceptance of these pricey technologies because of their advantages in revascularization therapies. 

Reusable devices are also widely used in Latin America because they are a cost-effective alternative for businesses looking to cut PCI expenses. On the markets for conventional PTCA balloon catheters and associated accessory devices, this reuse restriction will have a significant impact.

Key Companies & Market Share Insights

Interventional cardiology has a very crowded market. Boston Scientific, Medtronic, and Abbott Laboratories are a few of the well-known market leaders in the IC devices industry. These businesses have developed into dominant players as a result of their broad product ranges and capacity to meet a variety of market niches.

They are able to use aggressive pricing strategies because they could sell complete product bundles of the IC devices needed in cardiac catheterization labs for significantly less money. These companies have also been spending money on the creation of fresh goods for the highly profitable intravascular imaging industry and the coronary stent market.

For better market penetration and to maintain competition, businesses are utilizing tactics like new product launches and technological advancements. For instance, following the release of their respective next-generation DES, both Boston Scientific and Medtronic saw increases in share. In addition, Abbott Laboratories has been able to reclaim its significant market presence with the release of XIENCE Sierra DES in 2018 and XIENCE Sky-point in 2021. The global interventional cardiology market has some notable competitors, including :

  • Abbott Laboratories
  • Medtronic
  • Boston Scientific
  • Spectranetics
  • Cardinal Health
  • Philips Healthcare
  • Terumo
  • Alvimedica
  • Teleflex Medical
  • B. Braun
  • Biosensors International
  • Meril Life Sciences
  • ACIST Medical Systems
  • CID Vascular
  • Cook Medical
  • Medinol
  • Merit Medical Systems
  • NuMED
  • Opsens
  • Vascular Solutions
  • Zeon Medical

Interventional Cardiology Devices Market Report Scope 

Report Attribute


Market size value in 2022

USD 12.01 billion

Revenue forecast in 2030

USD 16.11 billion

Growth rate

CAGR of 3.7% from 2022 to 2030

Base year for estimation


Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Procedure (000’ units), unit volume (000’ units), ASP in USD, revenue in USD million/billion, CAGR from 2022 to 2030

Report coverage

Volume forecast, revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Product, region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; Germany; U.K.; France; Spain; Italy; Japan; China; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; Turkey

Key companies profiled

Abbott Laboratories; Medtronic; Boston Scientific; Terumo; B. Braun; BIOTRONIK; Biosensors International; Koninklijke Philips N.V.; Teleflex Medical; Meril Life Sciences; Merit Medical Systems; Becton; Dickinson and Company (BD)

Customization scope

Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Interventional Cardiology Devices Market Segmentation

This study projects volume and revenue growth at the international, regional, and national levels and analyses the most recent market developments and growth prospects in each of the sub-sectors from 2017 to 2030. Grand View Research has divided the global interventional cardiology market report into regions and products for the purposes of this study:

  • Product Outlook (Procedure; Unit Volume; ASP; Revenue, USD Million, 2017 - 2030)
    • Coronary Stents
      • DES
      • BMS
      • BRS
    • PTCA Balloon Catheters
      • Normal
      • Specialty (Includes cutting, scoring, and lithotripsy balloons)
      • DCB
    • Accessory Devices
      • PTCA Guidewires (Workhorse, Specialty)
      • Diagnostic Catheters
      • PTCA Guiding Catheters
      • Introducer Sheaths
    • Intravascular Imaging Catheters and Pressure Guidewires (IVUS Catheters, OCT Catheters, FFR Guidewires)
  • Regional Outlook (Procedure; Unit Volume; Revenue, USD Million, 2017 - 2030)
    • North America
      • U.S.
      • Canada
    • Europe (EU-5)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • Turkey



To Collaborate Scientific Professionals around the World

Conference Date June 28-29, 2023

For Sponsors & Exhibitors

Speaker Opportunity

Supported By

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Media partners & Collaborators & Sponsors


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner